A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

NCT06424444 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

421

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: Reproxalap ophthalmic solution (0.25%)
DRUG: Vehicle ophthalmic solution

Sponsor

Aldeyra Therapeutics, Inc.